Paul Barnard
Pulmonary Disease · Gilbert, AZNPI 1992706717
Payments from drug & device makers
Across 495 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$796
- Mylan Specialty L.p.$505
- Boehringer Ingelheim$491
- Jazz Pharmaceuticals Inc.$480
- plus $4K from 33 others
What the payments were for
- Consulting fees$160%
- Food & beverage$8,420100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 96 | $1,162 |
| AstraZeneca | 51 | $1,072 |
| Regeneron Healthcare Solutions, Inc. | 50 | $796 |
| Mylan Specialty L.p. | 34 | $505 |
| Boehringer Ingelheim | 23 | $491 |
| Jazz Pharmaceuticals Inc. | 23 | $480 |
| Amgen | 23 | $473 |
| Grifols USA, LLC | 22 | $441 |
| Sanofi | 20 | $405 |
| Harmony Biosciences LLC | 12 | $268 |
| Philips North America LLC | 16 | $236 |
| Advanced Respiratory, Inc | 27 | $231 |
| Baxter Healthcare | 14 | $212 |
| Actelion Pharmaceuticals US, Inc. | 8 | $205 |
| Sunovion Pharmaceuticals Inc. | 11 | $154 |
| Insmed, Inc. | 6 | $150 |
| Covis Pharma GmbH | 4 | $133 |
| Novartis | 7 | $113 |
| Genentech USA, Inc. | 6 | $107 |
| Mallinckrodt Hospital Products Inc. | 4 | $103 |
| UCB, Inc. | 5 | $84 |
| Electromed, Inc. | 5 | $82 |
| Johnson & Johnson | 1 | $76 |
| Shire North American Group Inc | 3 | $52 |
| Circassia Inc. | 3 | $51 |
| Pulmonx Corporation | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $46 |
| Gilead | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Merck | 2 | $29 |
| Boston Scientific | 1 | $28 |
| ZOLL Respicardia, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Itamar Medical Inc | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Apria Healthcare LLC | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,449 in reported general payments places this provider in the 65th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Gilbert
- Richard SueGilbert$624K
- Archan ShahGilbert$20K
- Harmeet GillGilbert$17K
- Amy BohanGilbert$17K
- Thomas SlobigGilbert$16K
- Wahaj AhmedGilbert$15K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.